MED
Medifast, Inc.
MED has slightly lower modeled downside risk, despite its lower overall score.
NIO
NIO Inc.
NIO has the edge over MED overall, supported by stronger fundamentals.
MED Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Strong |
MED's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
NIO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Stable | |
| Stable | |
| Unavailable |
NIO's revenue is currently strong, and its profitability and cash flow are stable. There isn't enough data to rate its balance sheet.
MED PE Valuation
MED has no meaningful PE right now: it lost money over the past year.
NIO PE Valuation
NIO has no meaningful PE right now: it lost money over the past year.
MED Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect MED's losses to shrink, with revenue holding steady.
NIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
NIO has the edge over MED on the outlook, with more favorable revenue expectations.
MED Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.68 | -18500% |
| Q2 2026 | -$2.32 | -803% |
| Q1 2026 | -$1.82 | -$1.18 |
| Q4 2025 | -$1.70 | -995% |
| Q3 2025 | $0.02 | -97% |
| Q2 2025 | $0.33 | -88% |
| Q1 2025 | -$0.64 | -110% |
| Q4 2024 | $0.19 | -98% |
MED has swung to a loss: it lost $3.68 per share over the past year, after a profit the year before.
NIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.29 | +$1.45 |
| Q1 2026 | -$0.60 | +$1.16 |
| Q4 2025 | -$1.06 | +$0.60 |
| Q3 2025 | -$1.59 | +$0.02 |
| Q2 2025 | -$1.74 | -$0.10 |
| Q1 2025 | -$1.76 | +$0.06 |
| Q4 2024 | -$1.66 | +$0.21 |
| Q3 2024 | -$1.61 | +$0.32 |
NIO has the edge over MED on earnings, with more consistent year-over-year improvement.
MED Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $72M | -19% |
| Q2 2026 | $76.4M | -28% |
| Q1 2026 | $76M | -34% |
| Q4 2025 | $75.1M | -37% |
| Q3 2025 | $89.4M | -36% |
| Q2 2025 | $105.6M | -37% |
| Q1 2025 | $115.7M | -34% |
| Q4 2024 | $119M | -38% |
MED's revenue has slid since its 2022 peak: $72M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -27% | -22 points |
| Q2 2026 | -5.7% | -4.7 points |
| Q1 2026 | -4.3% | -3.2 points |
| Q4 2025 | -10% | -11 points |
| Q3 2025 | -4.6% | -6.1 points |
| Q2 2025 | -1% | +3.7 points |
| Q1 2025 | -1.1% | -5.6 points |
| Q4 2024 | 0.6% | -3.9 points |
MED's operating margin was −27% last quarter, down 22 points from the same quarter a year ago, near the bottom of its range since 2019.
NIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $4.8B | +69% |
| Q1 2026 | $3.8B | +112% |
| Q4 2025 | $5.2B | +76% |
| Q3 2025 | $3.3B | +17% |
| Q2 2025 | $2.9B | +9% |
| Q1 2025 | $1.8B | +21% |
| Q4 2024 | $3B | +15% |
| Q3 2024 | $2.8B | -2.1% |
NIO has the edge over MED on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2.1% | +24 points |
| Q1 2026 | -1.2% | +52 points |
| Q4 2025 | 2.3% | +33 points |
| Q3 2025 | -16% | +12 points |
| Q2 2025 | -26% | +4 points |
| Q1 2025 | -53% | +1.1 points |
| Q4 2024 | -31% | +8.1 points |
| Q3 2024 | -28% | -2.6 points |
NIO has the edge over MED on profitability, with a higher operating margin.
MED Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.9M | -73% |
| Q2 2026 | $728K | +$5.5M |
| Q1 2026 | -$836K | -144% |
| Q4 2025 | -$6.6M | +$603K |
| Q3 2025 | $10.8M | +40% |
| Q2 2025 | -$4.8M | -143% |
| Q1 2025 | $1.9M | -65% |
| Q4 2024 | -$7.2M | -176% |
MED's free cash flow has turned negative after years in the green: −$4M over the past year.
NIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $0 | +$2.1B |
| Q1 2026 | $0 | $0 |
| Q4 2025 | $0 | +$391.3M |
| Q3 2025 | $0 | $0 |
| Q2 2025 | -$2.1B | +$73.9M |
| Q1 2025 | $0 | $0 |
| Q4 2024 | -$391.3M | -386% |
| Q2 2024 | -$2.2B | +$337.9M |
NIO has the edge over MED on cash flow, with more consistent year-over-year improvement.
MED Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +46K shares |
| 1 year | +1.7% | +190K shares |
| 3 years | +2.3% | +248K shares |
| 5 years | -5.1% | -604K shares |
| Available history | -7.7% | -936K shares |
MED has the edge over NIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $3.6M |
NIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +15.6M shares |
| 1 year | +12% | +267M shares |
| 3 years | +51% | +844M shares |
| 5 years | +60% | +933M shares |
| Available history | +143% | +1.5B shares |
NIO has 2.5B diluted shares, up 12% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
NIO hasn't bought back shares in the past year.
MED Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -2,976.8x | Net Cash |
| Q3 2025 | -12.1x | Net Cash |
| Q2 2025 | -7.2x | Net Cash |
| Q1 2025 | -14.3x | Net Cash |
| Q4 2024 | -5.8x | Net Cash |
| Q3 2024 | -4.9x | Net Cash |
| Q2 2024 | -2.3x | Net Cash |
| Q1 2024 | -1.0x | Net Cash |
MED has more cash than debt.
NIO Net Leverage
NIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MED Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.1 | Neutral |
| Stochastic | 72.6 | Neutral |
MED's weekly RSI is 59 (neutral) and its Stochastic is 73 (neutral).
NIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.7 | Neutral |
| Stochastic | 6.9 | Oversold |
NIO's weekly RSI is 31 (neutral) and its Stochastic is 7 (oversold).
MED PE vs Consumer Cyclical Sector
| Metric | MED | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
MED has no meaningful PE right now: it lost money over the past year.
NIO PE vs Consumer Cyclical Sector
NIO has no meaningful PE right now: it lost money over the past year.
MED Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.1 | 6% above |
| 20 week MA | $11.7 | 10% above |
| 50 week MA | $11.4 | 13% above |
| 100 week MA | $12.6 | 1.9% above |
| 200 week MA | $35.4 | 64% below |
MED has the edge over NIO on trend strength, trading above more of its moving averages.
NIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.36 | 9.2% below |
| 20 week MA | $4.01 | 24% below |
| 50 week MA | $4.81 | 37% below |
| 100 week MA | $4.85 | 37% below |
| 200 week MA | $6.03 | 49% below |
NIO is in a downtrend: it's below all five of its weekly moving averages, and 49% below its 200-week average.
MED Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $108.3 | $196.7 | +82% |
| 2021 | $196.7 | $204.2 | +3.8% |
| 2022 | $204.2 | $117.1 | -43% |
| 2023 | $117.1 | $67.2 | -43% |
| 2024 | $67.2 | $17.6 | -74% |
| 2025 | $17.6 | $11.0 | -37% |
| 2026 YTD | $11.0 | $12.9 | +16% |
MED has the edge over NIO on returns for 2026, with the stronger performance.
NIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.42 | $45.8 | +1791% |
| 2021 | $45.8 | $30.5 | -33% |
| 2022 | $30.5 | $11.0 | -64% |
| 2023 | $11.0 | $9.07 | -17% |
| 2024 | $9.07 | $4.48 | -51% |
| 2025 | $4.48 | $5.10 | +14% |
| 2026 YTD | $5.10 | $3.05 | -40% |
NIO's yearly returns have swung widely, from +1791% in 2020 to −64% in 2022. It's down 40% so far in 2026.